– 3D Bio is the first company implanting 3D-bioprinted living tissues in patients –
– Rapha Capital Management, LLC has been the lead investor in 3D Bio since its initial investment in 2019 –
MIAMI, Dec. 7, 2022 /PRNewswire/ — Popular Science magazine has awarded 3D Bio Therapeutics’ AuriNovo™, a 3D-bioprinted living human ear tissue implant, its top prize in “Best of What’s New – 2022” in the “Health” category. The first-in-human implantation of AuriNovo™ was chronicled in a front page story in the NYTimes earlier this year and was also announced in a prior press release.
Given the dramatic achievements in controlling the COVID-19 pandemic, last year’s top Popular Science award in Health went to Pfizer and Moderna’s COVID vaccines.
“This award is independent recognition of Rapha Capital’s exceptional ability to identify those companies at the earliest stages that eventually will go on to profoundly improve peoples’ lives”
Rapha Capital Management, LLC (“RCM“) is an investment manager focused on investments in early-stage biotechnology and medical device companies, based in Miami Florida. RCM’s mission is to use its unique abilities to identify those companies that it believes will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities. RCM manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. RCM, along with an experienced team of advisors and financial managers assembled by RCM, offers alternative asset management services to Rapha Capital BioVentures Fund I (“RCBVFI”), which was launched in April 2021. RCBVFI is focused on securing the investment lead, typically at Series A or just before, in target companies that RCM believes have developed transformative products, technologies, or processes that will drive long-term value creation for investors.
Rapha Capital PE Life Sciences Fund VI, (“RCPELSF VI”), RCM’s new Private Equity fund launched in September 2022, plans to maintain its focus on identifying great value in these times of market disruption in the broader life sciences and healthcare arena to make investments in mid- and later-stage companies, focused on companies in the biotechnology and medical devices spaces, in which it can be transformative.
“This award is independent recognition of Rapha Capital’s exceptional ability to identify those companies at the earliest stages that eventually will go on to profoundly improve peoples’ lives” said Dr. Kevin Slawin, founder and principal of RCM. “3D Bio’s success is an example RCM’s growing focus and expertise in the nascent field of regenerative medicine. RCM is also the founder of both Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc., investment targets for Rapha Capital PE Life Sciences Fund VI, that is building a portfolio in anti-aging science, which we believe will outgrow oncology in importance over the next decade,” he added.
About Rapha Capital Management, LLC
Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on identifying and managing strategic investments in early stage, non-public biotechnology and medical device companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc., a publicly traded company listed on NASDAQ. He is co-Inventor of the FDA,-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America’s Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. Rapha Capital Management offers alternative asset management services to the RCBVF I, which was launched in April 2021 and to RCPELSF VI, which was launched in September 2022. RCM is the founder of both Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc., investment targets for Rapha Capital PE Life Sciences Fund VI, that is building a portfolio in anti-aging science. Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc. reunite the team that founded Bellicum Pharmaceuticals and took it public in 2014 with a $161 million IPO. The team is retooling their original cell control technology with state-of-the-art advances towards their new goal of creating anti-aging products with a solid underlying scientific basis that actually work.
Contacts
Rapha Capital Management:
Email [email protected]
Visit https://raphacap.com
